SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers
hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases …

Children and adolescents exhibit a broad range of clinical outcomes from SARS-CoV-2
infection, with the majority having minimal to mild symptoms. Additionally, some succumb to …

Abstract Background In December 2019, a novel coronavirus disease (COVID-19) emerged
in Wuhan, China, with an incredible contagion rate. However, the vertical transmission of …

Background COVID-19, the coronavirus disease that emerged in December 2019, caused
drastic damage worldwide. At the beginning of the pandemic, available data suggested that …

Since the start of the coronavirus disease 2019 (COVID-19) pandemic, important insights
have been gained into virus biology and the host factors that modulate the human immune …

Background Inborn errors of immunity (IEI) and autoantibodies to type I interferons (IFNs)
underlie critical COVID-19 pneumonia in at least 15% of the patients, while the causes of …

Introduction Patients with immunodeficiency are usually more prone to worse outcomes of
infectious diseases. However, there are some disagreements in the context of COVID-19, for …

Background: The role of humoral immunity has been well established in reducing infection
risk and facilitating viral clearance in patients with COVID-19. However, the relationship …

A better understanding of COVID-19 in people with primary immunodeficiency (PI), rare
inherited defects in the immune system, is important for protecting this population, especially …

Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …